Lupin, Zydus Lifesciences ink licensing, supply pact for Saroglitazar Mg

Lupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by India's DCGI for treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news